Cargando…

Neratinib, an irreversible pan erB receptor tyrosine kinase inhibitor active for advanced HER2(+ )breast cancer

Detalles Bibliográficos
Autores principales:	Cortés-Funes, H, Mendiola, C, Manso, L, Ciruelos, E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Oral Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4284883/ http://dx.doi.org/10.1186/bcr2280

Ejemplares similares

The ErbB receptor tyrosine kinases and their roles in cancer
por: Hynes, NE
Publicado: (2003)

Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and HER2-Mutated Breast Cancer
por: Collins, Denis M., et al.
Publicado: (2019)

The role of irreversible pan-HER tyrosine kinase inhibitors in the treatment of HER2-Positive metastatic breast cancer
por: Wu, Zihong, et al.
Publicado: (2023)

Irreversible tyrosine kinase inhibitors induce the endocytosis and downregulation of ErbB2
por: Ghosh, Chinmoy, et al.
Publicado: (2023)

PI3K and MAPK Pathways as Targets for Combination with the Pan-HER Irreversible Inhibitor Neratinib in HER2-Positive Breast Cancer and TNBC by Kinome RNAi Screening
por: Lee, Jangsoon, et al.
Publicado: (2021)

Phase 1 Studies of Poziotinib, an Irreversible Pan-HER Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors
por: Kim, Tae Min, et al.
Publicado: (2018)

Circulating epithelial tumor cells in patients with metastatic breast cancer treated with bevacizumab
por: Manso, L, et al.
Publicado: (2009)

SOLTI (Solid Tumor Intensification) Group experience with high-dose chemotherapy treatment for early breast carcinoma
por: Funes, H Cortés, et al.
Publicado: (2005)

Raman Microspectroscopic Evidence for the Metabolism of a Tyrosine Kinase Inhibitor, Neratinib, in Cancer Cells
por: Aljakouch, Karim, et al.
Publicado: (2018)

Tyrosine kinase inhibitor neratinib attenuates liver fibrosis by targeting activated hepatic stellate cells
por: Park, Yong Joo, et al.
Publicado: (2020)

Lobular carcinoma of the breast: outcome of 205 patients
por: Vega, E, et al.
Publicado: (2011)

The role of Xeloda in metastasic breast cancer
por: Cortés-Funes, H
Publicado: (2005)

The EGFR/ErbB inhibitor neratinib modifies the neutrophil phosphoproteome and promotes apoptosis and clearance by airway macrophages
por: Herman, Kimberly D., et al.
Publicado: (2022)

S299: ORELABRUTINIB, AN IRREVERSIBLE INHIBITOR OF BRUTON’S TYROSINE KINASE, FOR TREATMENT OF PRIMARY IMMUNE THROMBOCYTOPENIA: RESULTS OF A RANDOMIZED, OPEN-LABEL PHASE II STUDY
por: Shi, Yan, et al.
Publicado: (2023)

Mechanisms of autoimmunity in mice lacking the mer membrane tyrosine kinase
por: Cohen, PL, et al.
Publicado: (2004)

Small Molecule Tyrosine Kinase Inhibitors of ErbB2/HER2/Neu in the Treatment of Aggressive Breast Cancer
por: Schroeder, Richard L., et al.
Publicado: (2014)

THER-01. PRECLINICAL DEVELOPMENT OF EO1001, A NOVEL IRREVERSIBLE BRAIN PENETRATING PAN-ErbB INHIBITOR
por: Shen, Wang, et al.
Publicado: (2019)

Adjuvant therapy after preoperative treatment for breast cancer
por: Ciruelos, E
Publicado: (2009)

Neratinib for HER2-positive breast cancer with an overlooked option
por: Guo, Liting, et al.
Publicado: (2023)

Single cell imaging of Bruton's Tyrosine Kinase using an irreversible inhibitor
por: Turetsky, Anna, et al.
Publicado: (2014)

Getting deep in the luminal B breast cancer subtype and its ki67 cut-off value
por: Ciruelos, E, et al.
Publicado: (2011)

Chaperone-mediated destruction of erbB2: relevance to tyrosine kinase inhibitors
por: Gee, Julia MW
Publicado: (2002)

Cyclin kinase inhibitors and interferons in lupus
por: Theofilopoulos, A
Publicado: (2003)

Transcriptome analysis of neratinib treated HER2 positive cancer model vs untreated cancer unravels the molecular mechanism of action of neratinib
por: Alkhezayem, Sara, et al.
Publicado: (2020)

A de novo nonsense mutation in the tyrosine kinase lyn in a patient with an early onset autoinflammatory phenotype
por: De Jesus, Adriana Almeida, et al.
Publicado: (2014)

Tyrosine kinase signalling in breast cancer: ErbB family receptor tyrosine kinases
por: Stern, David F
Publicado: (2000)

Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer
por: Canonici, Alexandra, et al.
Publicado: (2013)

Neratinib for the Treatment of Early-Stage HER2-Positive Breast Cancer
por: Miles, Jennifer, et al.
Publicado: (2018)

Neratinib for Extended Anti-HER2 Therapy in Early Breast Cancer
por: Budd, G. Thomas, et al.
Publicado: (2018)

Mechanisms of neratinib resistance in HER2-mutant metastatic breast cancer
por: Eli, Lisa D., et al.
Publicado: (2022)

Dacomitinib, an Irreversible Pan-ErbB Inhibitor Significantly Abrogates Growth in Head and Neck Cancer Models That Exhibit Low Response to Cetuximab
por: Ather, Ferdows, et al.
Publicado: (2013)

Targeting estrogen to kill ER-positive and ER-negative breast cancer
por: Jordan, VC
Publicado: (2005)

Real-World Analysis of the Efficacy and Safety of a Novel Irreversible HER2 Tyrosine Kinase Inhibitor Pyrotinib in Patients with HER2-Positive Metastatic Breast Cancer
por: Sun, Ying, et al.
Publicado: (2021)

Analysis of Gut Microbiome Using Explainable Machine Learning Predicts Risk of Diarrhea Associated With Tyrosine Kinase Inhibitor Neratinib: A Pilot Study
por: Wong, Chi Wah, et al.
Publicado: (2021)

The Lethality of [Pazopanib + HDAC Inhibitors] Is Enhanced by Neratinib
por: Booth, Laurence, et al.
Publicado: (2019)

Synergy between the erbB and transforming growth factor beta signaling networks: implications for molecular therapeutics in human neoplasia
por: Arteaga, CL
Publicado: (2003)

Activation of the ErbB3-AKT axis promotes melanoma cell survival and proliferation in response to RAF/MEK inhibition
por: Fattore, Luigi, et al.
Publicado: (2014)

A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation
por: Piha-Paul, Sarina A., et al.
Publicado: (2023)

Mutational Screening in Tyrosine-Kinase Domain of erbB1 And erbB2 Genes
por: ALONSO, Juan Manuel Fernández
Publicado: (2005)

Escape from HER family tyrosine kinase inhibitor therapy by the kinase inactive HER3
por: Sergina, Natalia V., et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_9ti0b7bkoi2vgjvskbqfhp1j8h